Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;29(9):e70495.
doi: 10.1111/jcmm.70495.

D- and L-Amino Acid Blood Concentrations Are Affected in Children With Duchenne Muscular Dystrophy

Affiliations

D- and L-Amino Acid Blood Concentrations Are Affected in Children With Duchenne Muscular Dystrophy

Martina Garofalo et al. J Cell Mol Med. 2025 May.

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked disease caused by the absence of functional dystrophin in the muscle cells. Recent untargeted metabolomics studies identified amino acid metabolism alterations as biochemical pathways potentially involved in DMD pathogenesis. Here, in a well-characterised cohort of DMD children and paediatric controls, we investigated by high-performance liquid chromatography (HPLC) the serum profile of a selected pool of amino acids in D- and L-configuration, including L-glutamate, L-glutamine, glycine, L-aspartate, D-aspartate, L-asparagine, L-serine, and D-serine. These amino acids are known to modulate neurotransmission and to play essential roles in energy and skeletal muscle metabolism. HPLC determinations highlighted a general amino acid deregulation in DMD compared to controls, including lower levels of L-aspartate, L-asparagine, D-serine, L-glutamine, and glycine and D-/Total serine ratio. In control subjects, we observed a significant positive correlation between L-glutamine and age, which lacked in affected children. Conversely, in DMD, we observed (i) a negative correlation of L-glutamate and L-aspartate with serum creatinine and creatine kinase levels; (ii) a direct correlation of serum L-glutamine/L-glutamate ratio with the fat-free mass index (as determined by dual energy X-ray absorptiometry) and with specific motor function scores (North Star Ambulatory Assessment); and (iii) no correlations between glucocorticoid treatment or cognitive function and the serum amino acid profile. Our study highlights significant correlations between serum L-glutamate levels, L-glutamine/L-glutamate ratio, and the multidimensional measures of muscle wasting and motor impairment, suggesting that peripheral glutamine-glutamate metabolism can be a suitable biomarker of disease severity and progression in DMD patients.

Keywords: Duchenne muscular dystrophy; D‐aspartate; D‐serine; amino acids; biomarker; glutamate; motor dysfunction; muscle wasting; serum.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(a) Representative HPLC chromatogram illustrating the amino acids peaks obtained from a serum sample; (b–m) Violin plots showing serum amino acid levels in DMD patients (n = 29) and controls (n = 24). Data are shown as median (bold line), 25°–75° percentiles (inner lines), min and max values (lower and upper violin extremities). *p < 0.05; **p < 0.01, Mann–Whitney U test.
FIGURE 2
FIGURE 2
Correlations between serum D‐aspartate, L‐aspartate, D−/Total aspartate ratio, D‐serine, L‐serine, D−/Total serine ratio and creatinine in DMD (n = 29) and control (n = 20) groups. Blue lines and grey shadows represent the best fit line and its 95% CI, respectively. *q < 0.05; Spearman's correlation test with FDR correction.
FIGURE 3
FIGURE 3
Correlations between serum L‐glutamate, L‐glutamine, L‐glutamine/L‐glutamate ratio, L‐asparagine, glycine, glycine/L‐serine ratio and creatinine in DMD (n = 29) and control (n = 20) groups. Blue lines and grey shadows represent the best fit line and its 95% CI, respectively. *q < 0.05; Spearman's correlation test with FDR correction.

Similar articles

References

    1. Aartsma‐Rus A., Ginjaar I. B., and Bushby K., “The Importance of Genetic Diagnosis for Duchenne Muscular Dystrophy,” Journal of Medical Genetics 53 (2016): 145–151, 10.1136/jmedgenet-2015-103387. - DOI - PMC - PubMed
    1. Coratti G., Pane M., Brogna C., et al., “Gain and Loss of Upper Limb Abilities in Duchenne Muscular Dystrophy Patients: A 24‐Month Study,” Neuromuscular Disorders 34 (2024): 75–82, 10.1016/j.nmd.2023.11.011. - DOI - PubMed
    1. Pane M., Lombardo M. E., Alfieri P., et al., “Attention Deficit Hyperactivity Disorder and Cognitive Function in Duchenne Muscular Dystrophy: Phenotype‐Genotype Correlation,” Journal of Pediatrics 161 (2012): 705–709, 10.1016/j.jpeds.2012.03.020. - DOI - PubMed
    1. Orso M., Migliore A., Polistena B., et al., “Duchenne Muscular Dystrophy in Italy: A Systematic Review of Epidemiology, Quality of Life, Treatment Adherence, and Economic Impact,” PLoS One 18 (2023): e0287774, 10.1371/journal.pone.0287774. - DOI - PMC - PubMed
    1. Crisafulli S., Sultana J., Fontana A., Salvo F., Messina S., and Trifirò G., “Global Epidemiology of Duchenne Muscular Dystrophy: An Updated Systematic Review and Meta‐Analysis,” Orphanet Journal of Rare Diseases 15 (2020): 141, 10.1186/s13023-020-01430-8. - DOI - PMC - PubMed

LinkOut - more resources